Hepion Pharmaceuticals, Inc.
HEPA
$0.06
-$0.03-35.23%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -46.59% | -54.45% | -55.79% | -39.86% | -28.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -62.00% | -78.77% | -80.56% | -82.84% | -73.76% |
| Operating Income | 62.00% | 78.77% | 80.56% | 82.84% | 73.76% |
| Income Before Tax | 76.49% | 81.86% | 48.78% | 64.85% | 57.28% |
| Income Tax Expenses | -- | -- | -- | 100.00% | 100.00% |
| Earnings from Continuing Operations | 76.49% | 81.86% | 37.25% | 59.62% | 52.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 76.49% | 81.86% | 37.25% | 59.62% | 52.19% |
| EBIT | 62.00% | 78.77% | 80.56% | 82.84% | 73.76% |
| EBITDA | 86.43% | 84.08% | 80.69% | 82.90% | 73.76% |
| EPS Basic | 99.51% | 99.69% | 97.86% | 94.01% | 84.73% |
| Normalized Basic EPS | 99.58% | 99.83% | 98.87% | 92.14% | 84.41% |
| EPS Diluted | 99.51% | 99.69% | 97.86% | 94.01% | 84.73% |
| Normalized Diluted EPS | 99.58% | 99.83% | 98.87% | 92.14% | 84.41% |
| Average Basic Shares Outstanding | 253.99% | 1,333.36% | 7,526.69% | 5,791.91% | 3,675.76% |
| Average Diluted Shares Outstanding | 253.99% | 1,333.36% | 7,526.69% | 5,791.91% | 3,675.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |